Cytomegalovirus (CMV)
Conditions
Keywords
Drug Therapy
Brief summary
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Interventions
OTHERNo Intervention
This is non-interventional study.
Sponsors
Takeda
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant signed an informed consent form. * Aged greater than or equal to (\>=) 18 years at the time of consent. * Received an HSCT/SOT. * Diagnosed with CMV infection/disease any time after the HSCT/SOT date. * Starting maribavir for the first time and in line with the Belgian reimbursement criteria.
Exclusion criteria
• Participant treated with maribavir before the start of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Effectiveness of Maribavir on CMV Viremia Clearance | Up to 16 weeks | CMV viraemia clearance is defined as last CMV quantitative polymerase chain reaction (PCR) during maribavir treatment. Viral clearance plasma CMV DNA concentration below the lower limit of quantification (\< LLOQ) less than \[\<\] 137 international units per milliliters (IU/mL). |
| Duration of Treatment | From treatment start to discontinuation of maribavir (up to 16 weeks) | Duration of treatment is defined as time from treatment start to discontinuation of maribavir. |
| Time to Viral Clearance | From treatment start to achievement of viral clearance (up to 2 years) | Time to viral clearance is defined as time from treatment start to achievement of viral clearance. |
| Percentage of Participants With Drug Resistance | Up to 2 years | Percentage of participants with drug resistance (UL97/UL27 genes) testing will be reported. |
| Number of Participants With Use of Maribavir in Daily Clinical Practice | Up to 16 weeks | — |
| Number of Participants Who Have Refractory CMV Infection With/Without Resistance, or Intolerance to a Previous CMV Treatment | Up to 16 weeks | Refractory CMV infection with resistance is defined as viral genetic alteration that decreases susceptibility to one or more antiviral drugs. |
| Percentage of Participants With Recurrence After Maribavir Treatment | Up to 2 years | Recurrence is defined as plasma CMV DNA concentration greater than or equal to (\>=) LLOQ in 2 consecutive plasma samples, after achieving confirmed viremia clearance. Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (\< LLOQ) that is \<137 IU/mL. |
| Number of Participants With Treatment Related Adverse Events (AEs) | Up to 2 years | The investigator is required to provide an assessment of the relationship of an AE to the studied drug(s), based on the consideration of all available information about the event, including temporal relationship to drug administration, recognized association with drug product/class, pharmacological plausibility, and alternative etiology (e.g., underlying illness, concurrent conditions, concomitant treatments). An related AE is defined as AE that follows a reasonable temporal sequence from administration of the medication, vaccine, or device (including the course after withdrawal of the medication), and for which a causal relationship is at least a reasonable possibility, i.e., the relationship cannot be ruled out, although factors other than the medication, vaccine, or device, such as underlying diseases, complications, concomitant drugs, and concurrent treatments, may also have contributed. |
Countries
Belgium
Contacts
STUDY_DIRECTORStudy Director
Takeda
Outcome results
None listed